Trial Profile

Open-Label, Single Dose, Parallel Group Pharmacokinetic Study of Ceftobiprole in Morbidly Obese and Non-Obese Patients.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 14 Jan 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ceftobiprole medocaril (Primary)
Indications Enterococcal infections; Methicillin-resistant Staphylococcus aureus infections; Pseudomonal infections; Streptococcal infections
Focus Pharmacokinetics
Sponsors Basilea Pharmaceutica

Most Recent Events

12 Apr 2016 Results presented at the 26th European Congress of Clinical Microbiology and Infectious Diseases
27 Aug 2012 Company (Basilea Pharmaceutica) added as an association and lead centre as reported by ClinicalTrials.gov record.
24 Dec 2009 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com